Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 14/20 | 0.59 |
| ▸ | MAPK11 | Q15759 | 7/20 | 0.59 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.47 |
| ▸ | MAPK12 | P53778 | 2/20 | 0.47 |
| ▸ | RAF1 | P04049 | 1/20 | 0.47 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.47 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14519383 | 0.88 | MAPK14 (0.44) | MAPK14MAPK11MAPK13MAPK12 | |
| SCHEMBL14411247 | 0.85 | MAPK14 (0.61) | MAPK14MAPK11MAPK13MAPK12KCNH2 | |
| SCHEMBL5253510 | 0.81 | MAPK14 (0.65) | MAPK14MAPK11MAPK13MAPK12RAF1 | |
| SCHEMBL5258115 | 0.79 | MAPK14 (0.52) | MAPK14MAPK11MAPK13MAPK12RAF1 | |
| SCHEMBL5448062 | 0.77 | MAPK14 (0.50) | MAPK14MAPK11MAPK13MAPK12KCNH2 | |
| SCHEMBL7857232 | 0.77 | MAPK14 (0.62) | MAPK14MAPK11MAPK13MAPK12RAF1 | |
| SCHEMBL5258501 | 0.77 | MAPK14 (0.62) | MAPK14MAPK11MAPK13MAPK12RAF1 | |
| SCHEMBL14519381 | 0.77 | TSHR (0.40) | MAPK14MAPK11MAPK13MAPK12RAF1 | |
| SCHEMBL5259384 | 0.76 | MAPK14 (0.52) | MAPK14MAPK11KCNH2 | |
| SCHEMBL5446608 | 0.76 | MAPK14 (0.53) | MAPK14MAPK11MAPK13MAPK12RAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070078146-A1 | Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma | PHARMACIA CORPORATION | 2007-04-05 | — | — | US | disclosed |
| US-20070078146-A1 | Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma | PHARMACIA CORPORATION | 2007-04-05 | — | — | US | disclosed |
| EP-1144403-B1 | SUBSTITUTED PYRAZOLES AS P38 KINASE INHIBITORS | SEARLE LLC (US) | 2004-10-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078146-A1 | Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma | MAPK1, MAPK3, MAPK4 | MAPK14 7/4885MAPK11 42/4885MAPK13 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.